Redx Pharma has a proven track record of creating innovative and commercially relevant small molecule drugs, with five current in-house and partnered assets in clinical development. The lead in-house programmes, RXC004, a porcupine inhibitor for Wnt-ligand dependent solid tumours, and RXC007, a ROCK2 inhibitor for broad fibrosis indications, are advancing through Phase II trials. Recently presented preclinical data suggest RXC007 can materially inhibit fibrosis in a range of lung fibrosis models. The earlier stage RXC008, a promising preclinical GI targeted ROCK inhibitor for Crohn’s related strictures, expands the fibrosis franchise further. Cash resources, coupled with June’s £34.3m equity raise, provide funding into CY2024. Clinical data from the two lead programmes are expected throughout the coming year. Our rNPV-based valuation remains £458m (vs £434m), or 138p/share.
07 Oct 2022
Redx Pharma: New data draws attention to promising fibrosis assets
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Redx Pharma: New data draws attention to promising fibrosis assets
Redx Pharma Plc (REDX:LON), 10.2 | Redx Pharma Plc (REDX:LON), 10.2
- Published:
07 Oct 2022 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
14
Redx Pharma has a proven track record of creating innovative and commercially relevant small molecule drugs, with five current in-house and partnered assets in clinical development. The lead in-house programmes, RXC004, a porcupine inhibitor for Wnt-ligand dependent solid tumours, and RXC007, a ROCK2 inhibitor for broad fibrosis indications, are advancing through Phase II trials. Recently presented preclinical data suggest RXC007 can materially inhibit fibrosis in a range of lung fibrosis models. The earlier stage RXC008, a promising preclinical GI targeted ROCK inhibitor for Crohn’s related strictures, expands the fibrosis franchise further. Cash resources, coupled with June’s £34.3m equity raise, provide funding into CY2024. Clinical data from the two lead programmes are expected throughout the coming year. Our rNPV-based valuation remains £458m (vs £434m), or 138p/share.